Synthetic data derivatives offer one potential solution to the aforementioned problems (9). Synthetic datasets are generated from existing datasets and maintain the statistical properties of the original dataset. Importantly, rows of observations in synthetic datasets do not correspond to identifiable individuals (rows of data) from the original dataset.
A s noted in this Editor's Page previously, the rising cost of developing new cardiovascular therapies cannot be sustained in the longterm (1) . Accordingly, there is a critical need for new methodologies that can improve the speed, efficiency, and success rate of efforts to develop new therapeutic strategies for cardiovascular disease (2) .
Although randomized clinical trials remain the gold standard to evaluate drug responsiveness, phase III clinical trials are costly due in part to the large numbers of patients that need to be enrolled and the long follow-up period needed to detect meaningful differences in survival or clinical outcomes (3) . As an alternative to randomized clinical trials, clinical effectiveness studies can be conducted to evaluate drug responsiveness in diverse patient populations (4, 5) . Such pragmatic approaches to evaluate drug responsiveness can be randomized or nonrandom- To fill this gap, data are needed, not only to know how best to treat individual patients, but also to develop and refine evidence-based treatment guidelines. Decision-makers in need of this information include policymakers, payers, health care organizations, clinicians, and patients. To precisely estimate effect sizes, researchers must have access to sufficiently large and representative datasets. Although data sharing is an option to increase the sample size of an eligible study population, many institutions lack the infrastructure and support to do so (8) . As a result, there are few networks of investigators who are willing and able to share data at the necessary scale in order to study drug responsiveness. This is a critical obstacle to progress, as data re-use and data sharing are essential for multisite, generalizable insights.
Synthetic data derivatives offer one potential solution to the aforementioned problems (9) . Synthetic datasets are generated from existing datasets and maintain the statistical properties of the original dataset. Importantly, rows of observations in synthetic datasets do not correspond to identifiable individuals (rows of data) from the original dataset.
Thus, synthetic data derivatives are quantitatively identical to patient-derived datasets, yet cannot be linked to the individuals from whom the data were derived (9) . Because synthetic data contain no protected health information, the datasets can be shared freely among investigators or those in industry, without raising patient privacy concerns. In addition, foraker@wustl.edu.
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